Valion Bio Terminates General Counsel Melinda Lackey; Entolimod Efficacy Study Begins
Valion Bio, Inc. terminated General Counsel and Senior Vice President of Legal Affairs Melinda Lackey, effective October 30, 2026, under a separation agreement signed October 31, 2026. The filing also reports that the Armed Forces Radiobiology Research Institute will evaluate the therapeutic efficacy of the company's lead candidate, Entolimod, with top-line results anticipated in early December.
Key points
- Lackey was notified of her termination on October 27, 2026, effective October 30, 2026.
- Severance is a $26,750 gross lump-sum payment, due no later than 30 days after the agreement's effective date, plus possible COBRA premium payments through November 30, 2026.
- Lackey forfeits unvested equity awards; vested stock options may be exercised only under the equity plan documents.
- The NIAID-funded study will test whether Entolimod given 24 hours after radiation exposure improves survival; top-line results are expected in early December.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.